NasdaqGS:AMGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. More Details


Snowflake Analysis

Fair value with mediocre balance sheet.


Similar Companies

Share Price & News

How has Amgen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMGN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.3%

AMGN

-4.0%

US Biotechs

-1.4%

US Market


1 Year Return

12.3%

AMGN

31.7%

US Biotechs

17.8%

US Market

Return vs Industry: AMGN underperformed the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: AMGN underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

AMGNIndustryMarket
7 Day-3.3%-4.0%-1.4%
30 Day-6.0%0.1%4.7%
90 Day-8.1%-3.5%8.2%
1 Year15.4%12.3%34.0%31.7%20.5%17.8%
3 Year41.8%30.1%18.7%12.8%42.2%32.7%
5 Year65.5%44.1%13.4%5.4%83.4%62.7%

Price Volatility Vs. Market

How volatile is Amgen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amgen undervalued compared to its fair value and its price relative to the market?

13.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMGN ($228.97) is trading below our estimate of fair value ($259.36)

Significantly Below Fair Value: AMGN is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: AMGN is good value based on its PE Ratio (18.6x) compared to the US Biotechs industry average (29.6x).

PE vs Market: AMGN is good value based on its PE Ratio (18.6x) compared to the US market (19x).


Price to Earnings Growth Ratio

PEG Ratio: AMGN is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: AMGN is overvalued based on its PB Ratio (12.6x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Amgen forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?

9.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMGN's forecast earnings growth (9% per year) is above the savings rate (2.2%).

Earnings vs Market: AMGN's earnings (9% per year) are forecast to grow slower than the US market (22.2% per year).

High Growth Earnings: AMGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: AMGN's revenue (3.8% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: AMGN's revenue (3.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AMGN's Return on Equity is forecast to be very high in 3 years time (77.5%).


Next Steps

Past Performance

How has Amgen performed over the past 5 years?

1.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMGN has high quality earnings.

Growing Profit Margin: AMGN's current net profit margins (30%) are lower than last year (33.8%).


Past Earnings Growth Analysis

Earnings Trend: AMGN's earnings have grown by 1% per year over the past 5 years.

Accelerating Growth: AMGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AMGN had negative earnings growth (-8.3%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).


Return on Equity

High ROE: Whilst AMGN's Return on Equity (68.48%) is outstanding, this metric is skewed due to their high level of debt.


Next Steps

Financial Health

How is Amgen's financial position?


Financial Position Analysis

Short Term Liabilities: AMGN's short term assets ($22.9B) exceed its short term liabilities ($10.5B).

Long Term Liabilities: AMGN's short term assets ($22.9B) do not cover its long term liabilities ($43.8B).


Debt to Equity History and Analysis

Debt Level: AMGN's debt to equity ratio (316.1%) is considered high.

Reducing Debt: AMGN's debt to equity ratio has increased from 116.2% to 316.1% over the past 5 years.

Debt Coverage: AMGN's debt is well covered by operating cash flow (32.3%).

Interest Coverage: AMGN's interest payments on its debt are well covered by EBIT (8.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Amgen current dividend yield, its reliability and sustainability?

2.81%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: AMGN's dividend (2.8%) is higher than the bottom 25% of dividend payers in the US market (1.64%).

High Dividend: AMGN's dividend (2.8%) is low compared to the top 25% of dividend payers in the US market (4.68%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, AMGN has been paying a dividend for less than 10 years.

Growing Dividend: AMGN's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (49.5%), AMGN's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: AMGN's dividends in 3 years are forecast to be well covered by earnings (40.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Bob Bradway (57 yo)

8.42yrs

Tenure

US$19,612,793

Compensation

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President from May 2010 . Mr. Bradway is responsible for the Amgen's global ...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD19.61M) is above average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Bradway
Chairman8.42yrsUS$19.61m0.085%
$ 114.0m
Jonathan Graham
Executive VP5.25yrsUS$7.24m0.0054%
$ 7.2m
David Reese
Executive Vice President of Research & Developmentno dataUS$6.54m0.0029%
$ 3.9m
Murdo Gordon
Executive VP of Global Commercial Operations2.08yrsUS$6.66m0.0011%
$ 1.5m
Peter Griffith
Executive VP & CFO0.75yrno datano data
Esteban Santos
Executive Vice President of Operations4.25yrsno data0.0059%
$ 7.9m
Linda Louie
VP of Finance & Chief Accounting Officer0.25yrno data0.00096%
$ 1.3m
Mike Zahigian
Senior VP & Chief Information Officer1.75yrsno datano data
Arvind Sood
Vice President of Investor Relations16.08yrsno datano data
Nancy Grygiel
Senior Vice President of Worldwide Compliance & Business Ethics and Chief Compliance Officer0.75yrno data0.00027%
$ 360.5k
Lori Johnston
Executive Vice President of Human Resources3.83yrsno data0.0027%
$ 3.6m
Victoria Blatter
Senior Vice President of U.S. Government Affairsno datano datano data

3.0yrs

Average Tenure

57yo

Average Age

Experienced Management: AMGN's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Bradway
Chairman8.42yrsUS$19.61m0.085%
$ 114.0m
Fred Hassan
Independent Director5.25yrsUS$343.61k0.0016%
$ 2.1m
Ronald Sugar
Independent Director10.25yrsUS$358.11k0.0027%
$ 3.6m
Robert Eckert
Lead Independent Director4.42yrsUS$396.53k0.000070%
$ 93.5k
Amy Miles
Independent Director0.25yrno datano data
Charles Holley
Independent Director3.67yrsUS$356.82k0.00022%
$ 293.8k
Greg Garland
Independent Director7yrsUS$361.11k0.0015%
$ 2.1m
Ellen Kullman
Independent Director4yrsUS$338.52k0.000070%
$ 93.5k
Brian Druker
Independent Director2.42yrsUS$345.16kno data
Tyler Jacks
Independent Director8.42yrsUS$339.11k0.00032%
$ 427.3k
Wanda Austin
Independent Director2.83yrsUS$347.53k0.00055%
$ 734.4k
R. Williams
Independent Director6yrsUS$339.72k0.00088%
$ 1.2m

4.8yrs

Average Tenure

64yo

Average Age

Experienced Board: AMGN's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Amgen Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amgen Inc.
  • Ticker: AMGN
  • Exchange: NasdaqGS
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$133.526b
  • Shares outstanding: 585.69m
  • Website: https://www.amgen.com

Number of Employees


Location

  • Amgen Inc.
  • One Amgen Center Drive
  • Thousand Oaks
  • California
  • 91320-1799
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 1983
AMGN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJun 1983
4332SEHK (The Stock Exchange of Hong Kong Ltd.)YesCommon StockHKHKDJun 1983
AMGNSWX (SIX Swiss Exchange)YesCommon StockCHCHFJun 1983
AMGXTRA (XETRA Trading Platform)YesCommon StockDEEURJun 1983
AMGDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1983
AMGNSNSE (Santiago Stock Exchange)YesCommon StockCLUSDJun 1983
0R0TLSE (London Stock Exchange)YesCommon StockGBUSDJun 1983
AMG-UETLX (Eurotlx)YesCommon StockITEURJun 1983
AMGNWBAG (Wiener Boerse AG)YesCommon StockATEURJun 1983
AMGNBASE (Buenos Aires Stock Exchange)CEDEAR EACH 5 REPR 1 (USD)ARARSSep 2000
AMGN34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH REPR 1 COM SHSBRBRLAug 2012

Biography

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience ar ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/23 00:23
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.